WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock

$5.69+0.13 (+2.34%)
Updated Jun 2, 2023
PRLD Price
$5.69
Fair Value Price
$6.34
Market Cap
$272.86M
52 Week Low
$4.20
52 Week High
$8.90
P/E
-2.38x
P/B
1.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$113.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$92M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PRLD Overview

Prelude Therapeutics Incorporated develops novel precision cancer medicines for underserved patients. PRT543 targets select solid tumors and myeloid malignancies; PRT811 targets solid tumors, including glioblastoma multiforme. Prelude Therapeutics was founded in 2016 and is headquartered in Wilmington, DE.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRLD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PRLD ($5.69) is undervalued by 10.2% relative to our estimate of its Fair Value price of $6.34 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PRLD ($5.69) is not significantly undervalued (10.2%) relative to our estimate of its Fair Value price of $6.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PRLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRLD due diligence checks available for Premium users.

Be the first to know about important PRLD news, forecast changes, insider trades & much more!

PRLD News

Valuation

PRLD fair value

Fair Value of PRLD stock based on Discounted Cash Flow (DCF)
Price
$5.69
Fair Value
$6.34
Undervalued by
10.20%
PRLD ($5.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRLD ($5.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PRLD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.38x
Industry
11.51x
Market
52.69x

PRLD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.56x
Industry
5.2x
PRLD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PRLD's financial health

Profit margin

Revenue
$0.0
Net Income
-$27.7M
Profit Margin
0%
PRLD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$198.3M
Liabilities
$23.0M
Debt to equity
0.13
PRLD's short-term assets ($175.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRLD's short-term assets ($175.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRLD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$30.1M
Investing
$18.0M
Financing
-$269.0k
PRLD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PRLD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PRLD$272.86M+2.34%-2.38x1.56x
NSTG$274.06M+1.05%-1.67x20.12x
ACRV$271.22M-0.40%N/A1.69x
RPHM$275.30M-4.10%-3.75x3.16x
XFOR$268.86M-0.90%-1.80x5.20x

Prelude Therapeutics Stock FAQ

What is Prelude Therapeutics's quote symbol?

(NASDAQ: PRLD) Prelude Therapeutics trades on the NASDAQ under the ticker symbol PRLD. Prelude Therapeutics stock quotes can also be displayed as NASDAQ: PRLD.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.

What is the 52 week high and low for Prelude Therapeutics (NASDAQ: PRLD)?

(NASDAQ: PRLD) Prelude Therapeutics's 52-week high was $8.90, and its 52-week low was $4.20. It is currently -36.07% from its 52-week high and 35.48% from its 52-week low.

How much is Prelude Therapeutics stock worth today?

(NASDAQ: PRLD) Prelude Therapeutics currently has 47,955,005 outstanding shares. With Prelude Therapeutics stock trading at $5.69 per share, the total value of Prelude Therapeutics stock (market capitalization) is $272.86M.

Prelude Therapeutics stock was originally listed at a price of $26.20 in Sep 25, 2020. If you had invested in Prelude Therapeutics stock at $26.20, your return over the last 2 years would have been -78.28%, for an annualized return of -53.4% (not including any dividends or dividend reinvestments).

How much is Prelude Therapeutics's stock price per share?

(NASDAQ: PRLD) Prelude Therapeutics stock price per share is $5.69 today (as of Jun 2, 2023).

What is Prelude Therapeutics's Market Cap?

(NASDAQ: PRLD) Prelude Therapeutics's market cap is $272.86M, as of Jun 5, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Prelude Therapeutics's market cap is calculated by multiplying PRLD's current stock price of $5.69 by PRLD's total outstanding shares of 47,955,005.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.